BR0213196A - Formulações farmacêuticas para liberação controlada de 4-amino-6,7-dimetóxi-2-(5-metanossulfonamido-1,2,3,4- tetrahidroisoquinol-2-il)-5-(2-piridil)quinazonila - Google Patents

Formulações farmacêuticas para liberação controlada de 4-amino-6,7-dimetóxi-2-(5-metanossulfonamido-1,2,3,4- tetrahidroisoquinol-2-il)-5-(2-piridil)quinazonila

Info

Publication number
BR0213196A
BR0213196A BR0213196-0A BR0213196A BR0213196A BR 0213196 A BR0213196 A BR 0213196A BR 0213196 A BR0213196 A BR 0213196A BR 0213196 A BR0213196 A BR 0213196A
Authority
BR
Brazil
Prior art keywords
pyridyl
amino
methanesulfonamido
dimethoxy
controlled release
Prior art date
Application number
BR0213196-0A
Other languages
English (en)
Inventor
John Douglas Davis
Michael John Humphrey
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0213196A publication Critical patent/BR0213196A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS PARA LIBERAçãO CONTROLADA DE 4-AMINO-6,7-DIMETóXI-2-(5-METANOSSULFONAMIDO-1,2,3,4- TETRAHIDROISOQUINOL-2-IL)-5-(2-PIRIDIL)QUINAZONILA". A invenção refere-se a uma formulação de liberação controlada para administração oral que compreende 4-amino-6,7-dimetóxi-2-(5-metanossulfonamido-1,2,3,4-tetrahidro isoquinol-2-il)-5-(2-piridil)quinazolina, ou um seu sal farmaceuticamente aceitável; e um auxiliar, diluente ou veículo; farmaceuticamente aceitável, em que esta formulação está adaptada para liberar pelo menos 50% em peso de 4-amino-6,7-dimetóxi-2-(5-metanossulfonamido-1,2,3,4-tetrahidro isoquinol-2-il)-5-(2-piridil)quinazolina, ou um seu sal farmaceuticamente aceitável, 6 horas depois no Aparelho 1 descrito em United States Pharmacopoeia 24 (2000), pp 1941-1943. com recipentes de 1 litro, cestos de 40 mesh (orifícios de 0,4 mm), uma velocidade de 100 rpm, e um meio de dissolução que consiste em 900 mL de ácido clorídrico 0,01 M que contém 0,7% p/v de cioreto de sódio a 37<198>C. As formulações de acordo com a invenção são adequadas para tratamento de BPH.
BR0213196-0A 2001-10-11 2002-09-30 Formulações farmacêuticas para liberação controlada de 4-amino-6,7-dimetóxi-2-(5-metanossulfonamido-1,2,3,4- tetrahidroisoquinol-2-il)-5-(2-piridil)quinazonila BR0213196A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations
PCT/IB2002/004040 WO2003032956A1 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number Publication Date
BR0213196A true BR0213196A (pt) 2004-08-31

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213196-0A BR0213196A (pt) 2001-10-11 2002-09-30 Formulações farmacêuticas para liberação controlada de 4-amino-6,7-dimetóxi-2-(5-metanossulfonamido-1,2,3,4- tetrahidroisoquinol-2-il)-5-(2-piridil)quinazonila

Country Status (32)

Country Link
EP (1) EP1434570B8 (pt)
JP (1) JP4131471B2 (pt)
KR (1) KR20050032510A (pt)
CN (1) CN1568180A (pt)
AP (1) AP2004003001A0 (pt)
AR (1) AR036782A1 (pt)
AT (1) ATE303135T1 (pt)
BR (1) BR0213196A (pt)
CA (1) CA2461168A1 (pt)
CO (1) CO5560534A2 (pt)
DE (1) DE60205925T2 (pt)
DK (1) DK1434570T3 (pt)
DO (1) DOP2002000464A (pt)
EA (1) EA006168B1 (pt)
ES (1) ES2246017T3 (pt)
GB (1) GB0124455D0 (pt)
GT (1) GT200200184A (pt)
HR (1) HRP20040261A2 (pt)
HU (1) HUP0600064A3 (pt)
IL (1) IL160969A0 (pt)
IS (1) IS7179A (pt)
MA (1) MA27075A1 (pt)
MX (1) MXPA04003293A (pt)
NO (1) NO20041520L (pt)
OA (1) OA12709A (pt)
PA (1) PA8556001A1 (pt)
PE (1) PE20030551A1 (pt)
PL (1) PL369666A1 (pt)
SV (1) SV2004001279A (pt)
UY (1) UY27477A1 (pt)
WO (1) WO2003032956A1 (pt)
ZA (1) ZA200401976B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
NZ711225A (en) 2013-03-14 2020-06-26 Amgen Inc A pharmaceutical formulation comprising omecamtiv mecarbil, processess and uses
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008526T2 (de) * 1990-07-02 1994-08-18 Bend Res Inc Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU779118B2 (en) * 2000-03-03 2005-01-06 Pfizer Inc. 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3, 4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs

Also Published As

Publication number Publication date
NO20041520L (no) 2004-04-05
GT200200184A (es) 2003-05-23
EP1434570B8 (en) 2005-10-26
DE60205925T2 (de) 2006-06-08
ES2246017T3 (es) 2006-02-01
DOP2002000464A (es) 2003-04-15
ATE303135T1 (de) 2005-09-15
GB0124455D0 (en) 2001-12-05
EA200400431A1 (ru) 2004-08-26
JP4131471B2 (ja) 2008-08-13
CO5560534A2 (es) 2005-09-30
DK1434570T3 (da) 2005-11-07
EP1434570A1 (en) 2004-07-07
KR20050032510A (ko) 2005-04-07
CA2461168A1 (en) 2003-04-24
UY27477A1 (es) 2003-05-30
PE20030551A1 (es) 2003-06-26
EA006168B1 (ru) 2005-10-27
DE60205925D1 (de) 2005-10-06
HUP0600064A3 (en) 2007-02-28
SV2004001279A (es) 2004-02-19
IS7179A (is) 2004-03-11
AR036782A1 (es) 2004-10-06
IL160969A0 (en) 2004-08-31
JP2005507909A (ja) 2005-03-24
EP1434570B1 (en) 2005-08-31
WO2003032956A1 (en) 2003-04-24
MA27075A1 (fr) 2004-12-20
PL369666A1 (en) 2005-05-02
OA12709A (en) 2006-06-26
PA8556001A1 (es) 2003-07-28
HUP0600064A2 (en) 2006-06-28
CN1568180A (zh) 2005-01-19
HRP20040261A2 (en) 2004-08-31
AP2004003001A0 (en) 2004-03-31
MXPA04003293A (es) 2004-07-23
ZA200401976B (en) 2004-07-12

Similar Documents

Publication Publication Date Title
NO20021728L (no) Pyrimidin derivater
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
DE60021749D1 (de) Pharmazeutische formulierung enthaltend tolterodin sowie ihre verwendung
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
BR0313732A (pt) Compostos de pirimido tendo atividade antiproliferativa
YU49202A (sh) Benzazolski derivati i njihova upotreba kao modulatora jnk
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
NO993027L (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
CA2539985A1 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2001047913A3 (de) Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung
EP1256344A4 (en) REMEDIES FOR ENDOTHELIN-INDUCED DISEASES
BR0213196A (pt) Formulações farmacêuticas para liberação controlada de 4-amino-6,7-dimetóxi-2-(5-metanossulfonamido-1,2,3,4- tetrahidroisoquinol-2-il)-5-(2-piridil)quinazonila
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0207102A8 (pt) forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.
MY137835A (en) Quinazoline derivatives as src tyrosine kinase inhibitors
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
EE05300B1 (et) Akrloldistamtsiini derivaati sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat
NO20050030L (no) Azolmethliden cyanid derivater og deres anvendelse som proteinkinase modulatorer
ECSP045045A (es) Formulaciones farmacéuticas de liberación controlada que comprende 4-amino-6,7-dimetoxi-2-(5-metanosulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil)quinazolina
CR7302A (es) Formulaciones farmaceuticas de liberacion controlada de 4-amino-6,7-dimetoxi-2-(5-metasulfonamido-1,2,3,4-tetrahidroisoquinol-2-il)-5-(2-piridil) quinazolina
JPH1135464A (ja) ３−アルコキシピリジン誘導体の血管内膜肥厚の予防または治療剤
BR0316486A (pt) Composição farmacêutica que compreende um antagonista do ltb4 e um inibidor da cox-2 ou um inibidor combinado da cox1/2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.